DeDora Capital Inc. Has $1.36 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

DeDora Capital Inc. lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 10.4% during the third quarter, HoldingsChannel reports. The firm owned 11,943 shares of the company’s stock after selling 1,383 shares during the quarter. DeDora Capital Inc.’s holdings in Merck & Co., Inc. were worth $1,356,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MRK. Itau Unibanco Holding S.A. acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at $39,000. Abich Financial Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 121.8% in the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares in the last quarter. Quarry LP acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at $42,000. Strategic Financial Concepts LLC boosted its holdings in shares of Merck & Co., Inc. by 1,475.6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after purchasing an additional 32,832 shares in the last quarter. Finally, Ruedi Wealth Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 27.7% during the 2nd quarter. Ruedi Wealth Management Inc. now owns 397 shares of the company’s stock valued at $49,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of several recent research reports. Evercore ISI raised Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. Truist Financial dropped their price objective on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 31st. Finally, Barclays decreased their price objective on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $131.62.

Merck & Co., Inc. Price Performance

MRK traded down $0.15 during trading on Tuesday, reaching $106.19. The stock had a trading volume of 1,176,730 shares, compared to its average volume of 8,745,440. The stock has a market cap of $268.96 billion, a PE ratio of 118.16, a PEG ratio of 1.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. Merck & Co., Inc. has a one year low of $99.80 and a one year high of $134.63. The business has a 50-day moving average of $114.16 and a 200-day moving average of $122.19.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The business had revenue of $16.10 billion during the quarter, compared to analyst estimates of $15.87 billion. During the same period last year, the business posted ($2.06) earnings per share. Merck & Co., Inc.’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 7.88 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.